◆Guangzhou Bostal has completed the acquisition of U.S.-based AustarPharma LLC, renamed it Bostal LLC, and finished the corporate integration.
◆Bostal successfully held the 20th Anniversary Celebration.
◆Bostal was selected as one of SRDI "Little Giant" Enterprises.
◆Bostal passed the US FDA inspection and the EU QP audit again.

◆ Bostal completed the series B1 financing.
◆ Gastric floating metformin hydrochloride sustained-release tablet was approved for market launch.
◆ Bostal was selected as one of SRDI small and medium-sized enterprises in Guangdong Province.
◆ Bostal's key research project of Guangdong Province, "Core Key Technology of Industrialization of New Gastric Retention Drug Delivery System", passed the acceptance test successfully.

◆ The new analytical laboratory located in the industrial park was completed and put into use.
◆ The complex injection workshop and the ointment workshop were completed and put into use.
◆ Bostal passed the EU QP audit, representing that the quality system met the EU GMP standard.
◆ Bostal was certified as a high-tech enterprise again.

◆ Bostal's first sterile nanocrystal manufacturing workshop was completed and put into use.
◆ Bostal completed the series B1 financing.
◆ Bostal's research platform was awarded with the title of "Guangdong Provincial Engineering Center for New Drug Delivery System".
◆ Bostal's high-end public service platform for R&D and industrialization of pharmaceutical formulation technologies passed the acceptance inspection of emerging industry projects successfully.

◆ The solid dosage workshop of Bostal manufacturing base was put into operation.
◆ Bostal passed the GMP compliance inspection by NMPA, and became an GMP-compliant enterprise in both China and the United States.
◆ Entecavir Tablet, the first self-developed product of Bostal, was approved for market launch.
◆ Bostal was awarded with the titles of "Guangzhou Demonstration Institution for Science and Technology Service" and "Guangzhou Demonstration Enterprise for Service and Trade".

◆ The site at Enterprise Accelerator passed the US FDA inspection again.
◆ Bostal was certified as a high-tech enterprise again.
◆ Bostal was included in the List of 2019 Guangzhou Future Unicorn Innovative Company.
◆ Bostal was selected as one of the Gazelle Enterprises in Huangpu District.

◆ Bostal passed the US FDA inspection without any defect identified, and became the first prescription drug manufacturer passing the US FDA inspection in Guangzhou.
◆ Guangzhou BioCR Co., Ltd, a wholly-owned subsidiary of Bostal, was officially registered and established.

◆ Groundbreaking for industrialization base.
◆ Bostal completed the series A financing.
◆ The core team was selected as one of the Guangzhou Entrepreneurship Teams.
◆ Ron Liu was selected as a candidate of the national major projects for talent development.

◆ The second-phase expansion project of the R&D center for sustained-release and controlled-release durgs was completed.
◆ Bostal was certified as a high-tech enterprise for the first time.
◆ Bostal was awarded with the title of “Guangzhou Enterprise R&D Institution”.
◆ The core team of Bostal was selected as one of the Guangdong Provincial Innovation and Entrepreneurship Teams.
◆ Ron Liu was selected as the one of the leading talents in the Guangzhou Development District.

◆ The construction of R&D center and oral solid dosage manufacturing workshop was completed and put into use at the Enterprise Accelerator.

◆ In October 2014, Bostal moved in the Technology Enterprise Accelerator at Guangzhou Development District, and built a R&D center for sustained-release and controlled-release drugs, and a manufacturing workshop of oral solid drugs.

◆ In July 2013, Bostal was established in the National Enterprise Incubator at Guangzhou Science City.